Hamby ME, Kavanagh S, Di Caro V, et al. Positive Impact of CT1812 Treatment on Plasma Biomarkers in Lower p-tau217 Subgroup Aligns with Clinical Benefits in Mild-to-Moderate AD Patients. Poster presented at AD/PD 2025; Vienna, Austria
Di Caro V, Cho E, Lizama B, et al. Identification of Molecular Correlates with CT1812 Treatment-related decrease in NfL CSF Levels Connected to Sigma-2 Receptor. Poster presented at AD/PD 2025; Vienna, Austria
Lizama BN, Pandey K, Duong D, et al. CSF Proteomic Biomarker Analysis from Phase 2 Study SHINE Identified Effects of S2R Modulator CT1812 in Alzheimer’s Disease. Poster presented at AD/PD 2025; Vienna, Austria
Lizama BN, Pandey K, Duong D, et al. Identification of CSF Proteins that Correlate with Cognitive Outcomes in Participants of Phase 2 Study SHINE evaluating Effects of CT1812 in Patients with Alzheimer’s Disease. Poster presented at AD/PD 2025; Vienna, Austria
Lizama BN, Keeling E, Cho E, et al. Sigma-2 receptor modulator CT1812 alters key pathways and rescues retinal pigment epithelium (RPE) functional deficits associated with dry age-related macular degeneration (AMD). Sci Rep 15, 4256 (2025). https://doi.org/10.1038/s41598-025-87921-9
DiCaro V, Lizama BN, Cho E, et al. Exploratory CSF Proteomics Biomarker Outcomes of The Phase 2 Clinical Trial SHINE to Assess The Effects of CT1812 in Alzheimer’s Patients. Poster presented at 2024 Alzheimer’s Association International Conference (AAIC); Philadelphia, PA.
Cho E, Caldwell J, Pandey K, et al. CSF Phosphoproteomics Biomarker Analysis from the Phase 2 Clinical Trial SHINE to Elucidate the Role of CT1812 in Alzheimer’s Disease. Poster presented at 2024 Alzheimer’s Association International Conference (AAIC); Philadelphia, PA.
Di Caro V, Cho E, Knezovich N, et al. Top-Line CSF Biomarker Outcomes From The Phase 2 Clinical Trial SHINE In Alzheimer’s Patients. Poster presented at 2024 Alzheimer’s Association International Conference (AAIC); Philadelphia, PA.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
Cognition Therapeutics assumes no responsibility for the content of third-party website. Neither does Cognition control, endorse or guarantee any aspect of your use of third-party sites. We encourage you to read and evaluate terms of use, privacy and other policies of the destination site as they may differ from Cognition’s policies.
